{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:36:43Z","timestamp":1790231803878,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:00:00Z","timestamp":1334016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/nrrheum.2012.40","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T10:38:06Z","timestamp":1334054286000},"page":"280-287","source":"Crossref","is-referenced-by-count":44,"title":["Developments in therapies for spondyloarthritis"],"prefix":"10.1038","volume":"8","author":[{"given":"Joachim","family":"Sieper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,10]]},"reference":[{"key":"BFnrrheum201240_CR1","doi-asserted-by":"publisher","unstructured":"van Tubergen, A. & Weber, U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. Nat. Rev. Rheumatol. \n                    http:\/\/dx.doi.org\/10.1038\/nrrheum.2012.33\n                    \n                  .","DOI":"10.1038\/nrrheum.2012.33"},{"key":"BFnrrheum201240_CR2","doi-asserted-by":"publisher","unstructured":"Rudwaleit, M. & Sieper, J. Referral strategies for an early diagnosis of axial spondyloarthritis. Nat. Rev. Rheumatol. \n                    http:\/\/dx.doi.org\/10.1038\/nrrheum.2012.39\n                    \n                  .","DOI":"10.1038\/nrrheum.2012.39"},{"key":"BFnrrheum201240_CR3","doi-asserted-by":"publisher","unstructured":"Tse, S. M. L. & Laxer, R. M. New advances in juvenile spondyloarthritis. Nat. Rev. Rheumatol. \n                    http:\/\/dx.doi.org\/10.1038\/nrrheum.2012.37\n                    \n                  .","DOI":"10.1038\/nrrheum.2012.37"},{"key":"BFnrrheum201240_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M.  et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit, M.  et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25\u201331 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor, W.  et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665\u20132673 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun, J.  et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70, 896\u2013904 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling, J.  et al. ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 65, 442\u2013452 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun, J.  et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. 62, 817\u2013824 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun, J.  et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. 65, 316\u2013320 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D van der Heijde","year":"2011","unstructured":"van der Heijde, D.  et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70, 905\u2013908 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27, 361\u2013368 (1984).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 4","key":"BFnrrheum201240_CR13","first-page":"iv61","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper, J. & Rudwaleit, M. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann. Rheum. Dis. 64 (Suppl. 4), iv61\u2013iv64 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR14","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D.  et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 2136\u20132146 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel, H.  et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 58, 1981\u20131991 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR16","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham, N.  et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60, 946\u2013954 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/ard.2010.139667","volume":"70","author":"IH Song","year":"2011","unstructured":"Song, I. H.  et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann. Rheum. Dis. 70, 590\u2013596 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR18","unstructured":"Certolizumab pegol in subjects with active axial spondyloarthritis. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201240_CR19","unstructured":"Study comparing etanercept (ETN) against a placebo for etanercept on a background nonsteroidal anti inflammatory drug (NSAIDs) in the treatment of early spondyloarthritis (SpA) patients who do not have X-ray structural changes (AS EARLY). ClinicalTrials.gov \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201240_CR20","unstructured":"Effect of golimumab in participants with active axial spondyloarthritis (P07642) (GO-AHEAD). ClinicalTrials.gov \n                    [online]\n                    \n                  , (2012)."},{"issue":"Suppl.","key":"BFnrrheum201240_CR21","first-page":"S970","volume":"63","author":"J Sieper","year":"2011","unstructured":"Sieper, J.  et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis\u2014results of the phase 3 study [abstract 2486A]. Arthritis Rheum. 63 (Suppl.), S970\u2013S971 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR22","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos, X.  et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2014early clinical response predicts long-term outcome. Rheumatology (Oxford) 50, 1690\u20131699 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201240_CR23","first-page":"238","volume":"28","author":"E Martin-Mola","year":"2010","unstructured":"Martin-Mola, E.  et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 28, 238\u2013245 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201240_CR24","doi-asserted-by":"publisher","unstructured":"Sieper, J.  et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2011-200358\n                    \n                  .","DOI":"10.1136\/annrheumdis-2011-200358"},{"key":"BFnrrheum201240_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/rheumatology\/kei046","volume":"44","author":"J Sieper","year":"2005","unstructured":"Sieper, J.  et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 44, 1525\u20131530 (2005).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201240_CR26","doi-asserted-by":"publisher","unstructured":"Braun, J.  et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2011-200308","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"BFnrrheum201240_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit, M., Listing, J., Brandt, J., Braun, J. & Sieper, J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor \u03b1 blockers in ankylosing spondylitis. Ann. Rheum. Dis. 63, 665\u2013670 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M.  et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J. Rheumatol. 36, 801\u2013808 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201240_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger, N.  et al. Predicting the outcome of ankylosing spondylitis therapy. Ann. Rheum. Dis. 70, 973\u2013981 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit, M.  et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann. Rheum. Dis. 67, 1276\u20131281 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR31","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1136\/ard.2007.072397","volume":"66","author":"MK de Vries","year":"2007","unstructured":"de Vries, M. K.  et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 66, 1252\u20131254 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR32","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/ard.2009.109702","volume":"68","author":"MK de Vries","year":"2009","unstructured":"de Vries, M. K.  et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann. Rheum. Dis. 68, 1787\u20131788 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert, F.  et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601\u2013608 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201240_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/art.23167","volume":"58","author":"M Breban","year":"2008","unstructured":"Breban, M.  et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 58, 88\u201397 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR35","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","volume":"47","author":"EK Li","year":"2008","unstructured":"Li, E. K.  et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 47, 1358\u20131363 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201240_CR36","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar3350","volume":"13","author":"D Mulleman","year":"2011","unstructured":"Mulleman, D.  et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res. Ther. 13, R82 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201240_CR37","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3054","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit, M., Van den Bosch, F., Kron, M., Kary, S. & Kupper, H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res. Ther. 12, R117 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201240_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie, E.  et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann. Rheum. Dis. 70, 157\u2013163 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel, H., Rudwaleit, M., Listing, J. & Sieper, J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. 64, 296\u2013298 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR40","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/art.27383","volume":"62","author":"IH Song","year":"2010","unstructured":"Song, I. H.  et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 62, 1290\u20131297 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR41","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1136\/ard.2010.145946","volume":"70","author":"IH Song","year":"2011","unstructured":"Song, I. H.  et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann. Rheum. Dis. 70, 1108\u20131110 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jbspin.2011.02.018","volume":"79","author":"FK Lekpa","year":"2012","unstructured":"Lekpa, F. K.  et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 79, 47\u201350 (2012).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum201240_CR43","unstructured":"A study of RoActemra\/Actemra (tocilizumab) in patients with ankylosing spondylitis who have failed treatment with NSAIDs. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrrheum201240_CR44","unstructured":"A study of RoActemra\/Actemra (tocilizumab) in patients with ankylosing spondylitis who have had an inadequate response to previous TNF antagonist therapy. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrrheum201240_CR45","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel, H.  et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the TH17-mediated adaptive immune response. Arthritis Res. Ther. 13, R95 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201240_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths, C. E.  et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118\u2013128 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201240_CR47","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber, W.  et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010).","journal-title":"Sci. Transl. Med."},{"issue":"Suppl. 3","key":"BFnrrheum201240_CR48","first-page":"127","volume":"70","author":"D Baeten","year":"2011","unstructured":"Baeten, D.  et al. The anti-IL-17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann. Rheum. Dis. 70 (Suppl. 3), 127 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR49","unstructured":"Ustekinumab for the treatment of patients with active ankylosing spondylitis (TOPAS). ClinicalTrials.gov \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrrheum201240_CR50","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.2008.091793","volume":"68","author":"R Landewe","year":"2009","unstructured":"Landewe, R., Dougados, M., Mielants, H., van der Tempel, H. & van der Heijde, D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann. Rheum. Dis. 68, 863\u2013867 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR51","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders, A.  et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 52, 1756\u20131765 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR52","first-page":"60","volume":"5","author":"JW Boersma","year":"1976","unstructured":"Boersma, J. W. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand. J. Rheumatol. 5, 60\u201364 (1976).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201240_CR53","doi-asserted-by":"publisher","unstructured":"Poddubnyy, D.  et al. Effect of non-steroidal anti-inflammatory drugs on radiographic progression in patients with axial spondyloartrhitis: results from the German Spondyloarthritis Inception Cohort. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2011-201252","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"BFnrrheum201240_CR54","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/ard.2010.133488","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados, M.  et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis. Ann. Rheum. Dis. 70, 249\u2013251 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR55","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.tem.2009.12.004","volume":"21","author":"KA Blackwell","year":"2010","unstructured":"Blackwell, K. A., Raisz, L. G. & Pilbeam, C. C. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol. Metab. 21, 294\u2013301 (2010).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnrrheum201240_CR56","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D.  et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063\u20133070 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR57","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D.  et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324\u20131331 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR58","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde, D.  et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201240_CR59","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M.  et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann. Rheum. Dis. 68, 1520\u20131527 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR60","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/ard.2010.147033","volume":"70","author":"IH Song","year":"2011","unstructured":"Song, I. H.  et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann. Rheum. Dis. 70, 1257\u20131263 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR61","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1002\/art.30393","volume":"63","author":"P Chiowchanwisawakit","year":"2011","unstructured":"Chiowchanwisawakit, P., Lambert, R. G., Conner-Spady, B. & Maksymowych, W. P. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum. 63, 2215\u20132225 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR62","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/art.23260","volume":"58","author":"J Sieper","year":"2008","unstructured":"Sieper, J., Appel, H., Braun, J. & Rudwaleit, M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 58, 649\u2013656 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR63","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/ncprheum0930","volume":"4","author":"H Appel","year":"2008","unstructured":"Appel, H., Rudwaleit, M. & Sieper, J. Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. Nat. Clin. Pract. Rheumatol. 4, 578\u2013579 (2008).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum201240_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/art.24132","volume":"60","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych, W. P.  et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 60, 93\u2013102 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR65","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/art.1780380507","volume":"38","author":"M Dougados","year":"1995","unstructured":"Dougados, M.  et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 38, 618\u2013627 (1995).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR66","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/art.1780391209","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg, D. O.  et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs cooperative study. Arthritis Rheum. 39, 2004\u20132012 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR67","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun, J.  et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359, 1187\u20131193 (2002).","journal-title":"Lancet"},{"key":"BFnrrheum201240_CR68","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/ar2953","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit, M.  et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res. Ther. 12, R43 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201240_CR69","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1136\/ard.2009.121533","volume":"69","author":"M Dougados","year":"2010","unstructured":"Dougados, M.  et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann. Rheum. Dis. 69, 1430\u20131435 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec, L.  et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann. Rheum. Dis. 71, 4\u201312 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR71","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/1529-0131(199907)42:7<1386::AID-ANR12>3.0.CO;2-E","volume":"42","author":"J Sieper","year":"1999","unstructured":"Sieper, J.  et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum. 42, 1386\u20131396 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR72","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/ard.2003.010710","volume":"63","author":"TK Kvien","year":"2004","unstructured":"Kvien, T. K. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann. Rheum. Dis. 63, 1113\u20131119 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/art.1780340103","volume":"34","author":"A Lauhio","year":"1991","unstructured":"Lauhio, A., Leirisalo-Repo, M., Lahdevirta, J., Saikku, P. & Repo, H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum. 34, 6\u201314 (1991).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR74","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/art.24431","volume":"60","author":"JD Carter","year":"2009","unstructured":"Carter, J. D.  et al. Chlamydiae as etiologic agents in chronic undifferentiated spondyloarthritis. Arthritis Rheum. 60, 1311\u20131316 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR75","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/art.27394","volume":"62","author":"JD Carter","year":"2010","unstructured":"Carter, J. D.  et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 62, 1298\u20131307 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR76","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun, J., Baraliakos, X., Listing, J. & Sieper, J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52, 2447\u20132451 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201240_CR77","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M.  et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68, 696\u2013701 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR78","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/ard.2008.103192","volume":"69","author":"J Sieper","year":"2010","unstructured":"Sieper, J.  et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann. Rheum. Dis. 69, 226\u2013229 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201240_CR79","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"D Wendling","year":"2011","unstructured":"Wendling, D.  et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin. Arthritis Rheum. 41, 503\u2013510 (2011).","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.40","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:31:27Z","timestamp":1684470687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2012.40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,10]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFnrrheum201240"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2012.40","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,10]]}}}